TII
3.5.2021 10:03:07 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Directed Energy Research Centre (DERC) has unveiled its Electromagnetic Compatibility (EMC) laboratories in Abu Dhabi, housed in a first of its kind facility in the Arab world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005336/en/
The facility is composed of three laboratories - an EMC semi-anechoic chamber, a pulsed power laboratory, and a low-noise emanation laboratory.
The DERC facility enables key technologies to be evaluated against electromagnetic compatibility and interference by reproducing man-made and natural electromagnetic hazards in the pulsed power and semi-anechoic chambers. The direct connection between the two chambers enables a diversity of experiments involving 100’s of kV nanosecond pulses and multi-megawatt microwaves systems. The laboratories have been designed to host different categories of equipment such as connected objects of the Internet of Things, drones and autonomous cars, telecommunications equipment, medical devices, automotive equipment, IT equipment and is fully automated for tests and measurements. A unique low-noise emanation lab has been built on DERC specifications that allow for the study of very low noises emitted by electronic systems.
Electromagnetic compatibility, or EMC, allows electronic devices that are near each other to operate without mutual interference, known as Electromagnetic Interference, EMI. The operation of electronic circuits can be compromised as they can radiate or pick up unwanted interference. Highlighting the significance of EMC is the fact that the number of devices connected wirelessly is constantly on the rise.
H.E. Faisal Al Bannai, Secretary General of ATRC , said: “The launch of these labs, which are the first and the largest in the Arab world, is aligned with the Ministry of Industry and Advanced Technology’s (MoIAT) ’Operation 300bn’ which aims to advance the industrial sector, a mandate which we fully support at ATRC as the organisation defining Abu Dhabi’s and the UAE’s research strategy across academia and industry. ATRC is investing in cutting-edge laboratories that will support in-country R&D and local industry, and encourage innovation in line with international standards. By opening these unique laboratories, non-existent before in the Arab region, we want to support innovators from prototype to a qualified system.”
DERC is pioneering research in high energy physics, and the effects of high intensity fields on different materials, systems, and environments. The Centre is committed to using its cutting-edge position in science to search for practical solutions that benefit society in diverse areas. In EMC/EMI, DERC’s research domains include modelling of the EM environment produced by human-made sources; design, production, and evaluation of antennas; innovative materials for EM shielding applications; modelling of the electro-thermal response of industrial systems; and lightning protection.
Dr. Chaouki Kasmi, Chief Researcher at Directed Energy Research Centre , said: “At DERC we support research on a wide range of topics in EMC and EMI on behalf of governments and enterprises to help create and maintain advanced electronic systems. We are excited to announce the launch of the EMC labs in Abu Dhabi. They will help in pre-qualification of electronics against Electromagnetic Compatibility and Interference Standards as well as hardening of critical infrastructures to operate safely in harsh environments.”
“Many electromagnetic compatibility standards have been introduced over the years, making EMC a key part of the electronics design process,” Dr. Kasmi said. “With standards now implemented and enforced globally, manufacturers have to ensure that new electronic products meet the relevant EMC standards.”
For more information about Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005336/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom